This study highlighted RBP7 as a novel prognostic biomarker and is another piece of evidence that the SREBP1-dependent lipogenesis is a promising target to disrupt tumorigenesis and tumor progression [90]. This evidence concerns the gene SREBF1 and neoplasm.